SNTS - Santarus Inc. (Naz GM)

[Klipper22]

We hit this on the bottom and took the quick green. Not sure if the news today will make it roll higher or not.

Santarus Inc.
10590 West Ocean Air Drive
Suite 200
San Diego, CA 92130
United States - Map
Phone: 858-314-5700
Fax: 858-314-5701
Web Site: http://www.santarus.com

DETAILS
Index Membership: N/A
Sector: Healthcare
Industry: Drug Manufacturers - Other
Full Time Employees: 338

BUSINESS SUMMARY
Santarus, Inc., a specialty pharmaceutical company, engages in the acqusition, development, and commercialization of proprietary products and therapies that treat gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD) in the United States. It offers Zegerid family of products, which are proprietary immediate-release formulations that combine omeprazole, a proton pump inhibitor (PPI), and one or more antacids. The company's products are prescribed for the treatment of upper gastrointestinal diseases and disorders, including heartburn and other symptoms associated with GERD, erosive esophagitis, upper gastrointestinal bleeding, and gastric and duodenal ulcers. Santarus offers products in capsule, powder for oral suspension, and chewable tablet dosage forms. It sells its approved products to pharmaceutical wholesalers, who in turn distribute the products to retail pharmacies, mail order pharmacies, hospitals, and other institutional customers. Santarus has a strategic alliance with Schering-Plough Healthcare Products, Inc. to develop, manufacture, and sell over the counter products with the lower dosage strength of 20 mg of omeprazole in the United States and Canada; and a license agreement with the University of Missouri for its patents and pending patent applications relating to specific formulations of PPIs with antacids and other buffering agents. The company was founded in 1996 and is headquartered in San Diego, California.

Shares Outstanding: 51.28M
Float: 32.03M
% Held by Insiders: 0.13%
% Held by Institutions: 79.20%

http://stockcharts.com/h-sc/ui?s=snt...d=p47849470930

[Klipper22]

The PR:

Santarus Receives Previously Announced $5 Million Payment Under OTC License Agreement with Schering-Plough
Monday August 20, 4:00 am ET

SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS - News), a specialty pharmaceutical company, today reported that it has received the $5 million milestone payment previously announced on July 20, 2007 relating to progress on clinical product development strategy under its over-the-counter (OTC) license agreement with Schering-Plough HealthCare Products, Inc. for proton pump inhibitor (PPI) products using Santarus' patented PPI technology.

Under the terms of the OTC license agreement, Schering-Plough is responsible for the development, manufacturing and commercialization of OTC products using Santarus' PPI technology with the lower dosage strength of 20 mg of omeprazole for heartburn-related indications in the U.S. and Canada. Santarus will continue to manufacture, promote and sell its ZEGERID® (omeprazole/sodium bicarbonate) prescription products in both 20 mg and 40 mg dosage strengths of omeprazole in the U.S. prescription market for PPI products.

In addition to the $15 million upfront license fee received in November 2006 and this $5 million milestone, the company may receive up to an additional $60 million in milestone payments upon the achievement of certain regulatory and sales milestones. Santarus will also be entitled to a low double-digit royalty, subject to adjustment in certain circumstances, on net sales of any OTC products sold by Schering-Plough under the license agreement. In turn, Santarus will be obligated to pay royalties to the University of Missouri on net sales of any such OTC products.

About Santarus

[greencat]

SNTS making a big move. Not a buy area but will watch after a pulllback.

SNTS Chart